Trial Profile

An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EVO 756 (Primary)
Indications Chronic urticaria; Cold Urticaria; Familial dermographism
Focus Adverse reactions
Sponsors Evommune

Most Recent Events

02 Sep 2025 According to an Evommune media release, company will host a webcast to review the data being presented at EADV.
02 Sep 2025 According to an Evommune media release, full data set from this trial was accepted for a late-breaker oral presentation at the upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress being held in Paris, France from September 17-20, 2025.
18 Jun 2025 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com